UNITED THERAPEUTICS (UTHR) CFO exercises 10K options, sells 10K shares under 10b5-1 plan

Q: Was the UNITED THERAPEUTICS (UTHR) CFO’s share sale pre-planned under a Rule 10b5-1 plan?

Yes. A footnote states the option exercise and subsequent sales were made under a Rule 10b5-1 trading plan entered into on October 31, 2025, indicating the transactions were scheduled in advance rather than timed discretionarily.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a pre-planned transaction. On April 9, 2026, he exercised options for 10,000 shares of Common Stock at an exercise price of $135.42 per share.

On the same date, he sold a total of 10,000 shares of Common Stock in multiple open-market trades at prices reported between about $574.18 and $582.30. These transactions were made under a Rule 10b5-1 trading plan entered into on October 31, 2025, indicating they were pre-scheduled.

Following the transactions, Edgemond directly owned 18,876 shares of UNITED THERAPEUTICS Common Stock, maintaining a meaningful equity stake while monetizing the shares received from the option exercise.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($5,778,922)

Net Sell 10 txns

Insider EDGEMOND JAMES

Role CFO AND TREASURER

Sold 10,000 shs ($5.78M)

Type	Security	Shares	Price	Value
Exercise	Stock Option	10,000	$0.00	--
Exercise	Common Stock	10,000	$135.42	$1.35M
Sale	Common Stock	560	$574.868	$322K
Sale	Common Stock	1,956	$575.5272	$1.13M
Sale	Common Stock	1,586	$576.6268	$915K
Sale	Common Stock	1,617	$577.7654	$934K
Sale	Common Stock	1,139	$578.5244	$659K
Sale	Common Stock	1,224	$579.7491	$710K
Sale	Common Stock	1,756	$580.6392	$1.02M
Sale	Common Stock	162	$582.3023	$94K

Holdings After Transaction: Stock Option — 102,500 shares (Direct); Common Stock — 28,876 shares (Direct)

Footnotes (1)

This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $574.18 to $575.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $575.18 to $576.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $576.18 to $577.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $577.19 to $578.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $578.22 to $579.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $579.24 to $580.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $580.24 to $581.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $581.25 to $581.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Options exercised: 10,000 shares Exercise price: $135.42 per share Shares sold: 10,000 shares +4 more

7 metrics

Options exercised 10,000 shares Stock option exercise into Common Stock on April 9, 2026

Exercise price $135.42 per share Exercise price of stock options converted on April 9, 2026

Shares sold 10,000 shares Total Common Stock sold in open-market trades on April 9, 2026

Example sale price $574.868 per share One tranche of 560 shares of Common Stock sold

Highest reported sale price $582.3023 per share Tranche of 162 shares of Common Stock sold

Shares held after 18,876 shares Direct Common Stock ownership following all April 9, 2026 trades

Rule 10b5-1 plan date October 31, 2025 Date the trading plan governing these transactions was entered

Key Terms

Rule 10b5-1 trading plan, stock options, weighted average price, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

stock options financial

"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan..."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

weighted average price financial

"The price reported above reflects the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Form 4 Insider Transactions: What Each Field Means →

04/10/2026 - 04:33 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDGEMOND JAMES

(Last)

(First)

(Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING

MARYLAND

20910

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CFO AND TREASURER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/09/2026		M⁽¹⁾		10,000	A	$135.42	28,876	D
Common Stock	04/09/2026		S⁽¹⁾		560	D	$574.868⁽²⁾	28,316	D
Common Stock	04/09/2026		S⁽¹⁾		1,956	D	$575.5272⁽³⁾	26,360	D
Common Stock	04/09/2026		S⁽¹⁾		1,586	D	$576.6268⁽⁴⁾	24,774	D
Common Stock	04/09/2026		S⁽¹⁾		1,617	D	$577.7654⁽⁵⁾	23,157	D
Common Stock	04/09/2026		S⁽¹⁾		1,139	D	$578.5244⁽⁶⁾	22,018	D
Common Stock	04/09/2026		S⁽¹⁾		1,224	D	$579.7491⁽⁷⁾	20,794	D
Common Stock	04/09/2026		S⁽¹⁾		1,756	D	$580.6392⁽⁸⁾	19,038	D
Common Stock	04/09/2026		S⁽¹⁾		162	D	$582.3023⁽⁹⁾	18,876	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$135.42	04/09/2026		M⁽¹⁾			10,000	03/15/2023	03/15/2027	Common Stock	10,000	$0.00	102,500	D

Explanation of Responses:

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.

2. This transaction was executed in multiple trades at prices ranging from $574.18 to $575.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $575.18 to $576.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $576.18 to $577.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $577.19 to $578.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $578.22 to $579.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $579.24 to $580.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $580.24 to $581.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $581.25 to $581.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did UNITED THERAPEUTICS (UTHR) CFO James Edgemond report in this Form 4?

CFO James Edgemond reported exercising options for 10,000 UNITED THERAPEUTICS shares and selling 10,000 shares on April 9, 2026. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan and left him holding 18,876 shares directly.

How many UNITED THERAPEUTICS (UTHR) shares did the CFO exercise and at what price?

He exercised stock options covering 10,000 UNITED THERAPEUTICS shares at an exercise price of $135.42 per share. This converted his derivative option position into Common Stock before the same-day sales disclosed in the filing.

How many UNITED THERAPEUTICS (UTHR) shares did the CFO sell and at what prices?

He sold a total of 10,000 UNITED THERAPEUTICS Common shares in multiple open-market trades. Reported weighted average sale prices ranged roughly from $574.18 to $582.30 per share, with detailed price ranges noted for each trade group.

How many UNITED THERAPEUTICS (UTHR) shares does the CFO hold after these transactions?

After completing the option exercise and related sales, CFO James Edgemond directly owned 18,876 UNITED THERAPEUTICS Common shares. This figure reflects his position following all transactions reported for April 9, 2026 in the Form 4.

What overall pattern does the UNITED THERAPEUTICS (UTHR) Form 4 show for the CFO?

The Form 4 shows an exercise-and-sell pattern: 10,000 options exercised at $135.42, then 10,000 shares sold at market prices around the high-$570s to low-$580s, executed under a Rule 10b5-1 trading plan, with 18,876 shares retained.